MerTK mediates STAT3–KRAS/SRC-signaling axis for glioma stem cell maintenance
- 19 March 2018
- journal article
- research article
- Published by Taylor & Francis in Artificial Cells, Nanomedicine, and Biotechnology
- Vol. 46 (sup2) , 87-95
Abstract
Receptor tyrosine kinase Mer (MerTK) has been shown to be highly expressed in Glioblastoma multiforme (GBM) in comparison to its healthy counterpart and is implicated in brain tumorigenesis. Clarifying the underlying mechanism of MerTK induced invasiveness would result in novel strategies to improve patient’s response to chemotherapeutics. In vitro and in vivo assays were performed to examine the functional role of cancer stem sell (CSC) maintenance in MerTK associated invasiveness. In this article, we demonstrate that apart from GBM cells, MerTK is also upregulated in GBM stem-like cells and associated with an increased infiltrative potential of brain tumors in vivo. Silencing of MerTK suppressed the self-renewal of patient-derived GBM stem-like cells. The signaling mechanisms by which MerTK contributes to CSC maintenance have largely been obscure. Molecular analyses revealed that high expression of the signal transducer and activator of transcription 3 (STAT3)- Kirsten rat sarcoma viral oncogene homolog (KRAS) and proto-oncogene tyrosine-protein kinase SRC axis supports MerTK-induced CSC maintenance in GBM spheroids. Furthermore, a short-hairpin RNA-mediated MerTK knockdown effectively blocked invasiveness and N-cadherin expression in mouse xenografts. Collectively, our results uncover a critical function of MerTK in CSC maintenance. Considering the low basal level of MerTK expression in healthy brain cells, evaluation of MerTK as a therapeutic target should advance the research into better therapeutics for GBM.Keywords
Funding Information
- National Research Foundation
- Ministry of Science, ICT and Future Planning (NRF-2015M2A2A7A01044998, NRF-2016R1C1B2010851)
This publication has 29 references indexed in Scilit:
- MERTK receptor tyrosine kinase is a therapeutic target in melanomaJournal of Clinical Investigation, 2013
- Biology, genetics and imaging of glial cell tumoursBritish Journal of Radiology, 2011
- Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumorsExpert Opinion on Therapeutic Targets, 2010
- Inhibition of Mer and Axl Receptor Tyrosine Kinases in Astrocytoma Cells Leads to Increased Apoptosis and Improved ChemosensitivityMolecular Cancer Therapeutics, 2010
- Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and miceNeuro-Oncology, 2010
- Immunobiology of the TAM receptorsNature Reviews Immunology, 2008
- TAM Receptor Tyrosine Kinases: Biologic Functions, Signaling, and Potential Therapeutic Targeting in Human Cancer2008
- The 2007 WHO Classification of Tumours of the Central Nervous SystemActa Neuropathologica, 2007
- Glioma stem cells promote radioresistance by preferential activation of the DNA damage responseNature, 2006
- An implantable guide-screw system for brain tumor studies in small animalsJournal of Neurosurgery, 2000